Cambridge, UK, 15 February 2021: Chesterford Research Park is delighted to welcome material research company Superdielectrics to the Park’s prestigious Science Village. Superdielectrics is developing high energy density, low cost, low environmental impact electrical energy storage devices that will help create a clean and sustainable global energy and transportation system. Supercapacitors store energy using electrodes and electrolytes and both charge and deliver energy quickly, unlike conventional batteries which perform the same task in a much slower way with…

Cambridge, 15th February 2021: The Babraham Research Campus is delighted to welcome the charity Kidney Research UK as the latest organisation to pledge strategic and financial support to its Accelerate@Babraham initiative. The additional funding boosts the ability of the Campus to continue to support and sustain innovation in early science concepts and nurture new life science companies across the Cambridge cluster.Now in its fourth year, Accelerate@Babraham supports ambitious early stage life science ventures within the Babraham Research Campus’ active community. By…

Fast growing food safety testing firm Curtis Analytics relocates to Discovery Park Entrepreneurial scientist Dr Tanya Curtis plans further expansion & new business ideas Sandwich, Kent, February 15 2021 – Fast-growing food safety testing firm Curtis Analytics has relocated to Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, taking advantage of its grow-on space and high specification facilities. The company is a leader in the automated detection of asparagine, a precursor of the potentially carcinogenic (cancer causing) chemical…

A technology-driven spin out that looks to transform cell production is the latest business to move into The Biosphere lab facility on Newcastle Helix. Moving from the International Centre for Life, CellulaREvolution spun-out of Newcastle University in 2019 and are currently working on bringing their continuous cell culturing technologies, that aid the production of ‘clean meat’ to the market. This revolutionary new approach could transform this industry. The company’s bioreactor enables large quantities of adherent cells to be grown or manufactured. This technology means cells can be created…

Results from the first major business survey for 2021 by the Chambers of Commerce on Brexit found that half (49%) of  exporters  are  facing difficulties in adapting to the changes in the trade of goods following the ratification of the UK-EU Trade and Cooperation Agreement (TCA) on 1 January 2021. The survey sought to understand the extent to which businesses found it easy or difficult to adapt to changes in trading goods and/or services and moving people in the month since the ratification of the TCA. Businesses reported the highest proportion of difficulties in adapting to changes in…

Cambridge, UK, and New York City, USA, 11 February 2021: Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced the start of a clinical trial of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors. ART0380 was originally in-licensed from The University of Texas MD Anderson Cancer Center and ShangPharma Innovation in 2019.  The molecule was jointly developed as part of a collaboration between ShangPharma and MD Anderson’s…

Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide. The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product and clinical testing capabilities all under one organization — extending the 12-month drug development…

Cambridge, UK, 09 February 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of John Montana, PhD, as a Non-Executive Director. Expansion of the Board of Directors will support the Company’s further growth. Dr Montana brings over 30 years’ drug discovery and development experience across the pharmaceutical, biotech, and contract research sectors. Dr Montana is currently Operating Partner at Forbion, the life science venture capital firm. His previous roles have included Corporate Vice…

“The programme has been specially designed to support MedTech, Diagnostic and Digital Health, including service delivery, ventures to successfully engage investors needed to support their future growth, commercialise scientific discovery and solve global health and environmental challenges. If the last twelve months have taught us anything it is that solutions to many of our current problems are within the hands of the scientific community. Our ultimate aim is to help them make sure those solutions make it out of the lab and into the world”.   Richard Hebdon, Innovate UK’s Interim Deputy…

Research Triangle Park, NC, USA and Cambridge, UK, 4 February 2021 -- Inivata, a leader in liquid biopsy, today announces it has raised $35 million (£25.7 million) in a second close of a Series C financing round. The round was led by Soleus Capital, who were joined by new investors including Janus Henderson Investors and Farallon Capital alongside existing investor IP Group. This latest funding takes the total raised in the Series C to $60 million and follows the $25 million invested by NeoGenomics, Inc (NASDAQ: NEO) in 2020, alongside the formation of a strategic collaboration with Inivata.…